Scholar Rock Holding (SRRK)
Scholar Rock Holding on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
22.2M
Short interest
settlement 2026-10-15
12.7
Days to cover
+3.4 days vs prior
69.9%
Short share of volume
2026-11-02
177,778
Fails to deliver
settlement 2026-10-09
Fri 13 Nov
Next earnings
estimated date
$12.0M
Insider flow, 90 days
6 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in SRRK is 22,175,999 shares, up 2,768,293 shares over the last month. Over the last 48 readings it ranged from 14,173,937 shares (15 July 2025) to 22,722,119 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 1.7M shares a day that is 12.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/srrk" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 22,175,999 | -2.4% | 1,743,772 | 12.72 |
| 2026-09-30 | 22,722,119 | +17.1% | 2,437,734 | 9.32 |
| 2026-09-15 | 19,407,706 | +7.8% | 1,791,853 | 10.83 |
| 2026-08-31 | 18,008,058 | -1.2% | 1,172,523 | 15.36 |
| 2026-08-14 | 18,218,515 | +3.1% | 919,253 | 19.82 |
| 2026-07-31 | 17,667,182 | +0.4% | 1,088,801 | 16.23 |
| 2026-07-15 | 17,597,172 | -4.2% | 1,089,596 | 16.15 |
| 2026-06-30 | 18,375,421 | +9.8% | 2,554,061 | 7.19 |
| 2026-06-15 | 16,731,033 | +1.8% | 1,035,621 | 16.16 |
| 2026-05-29 | 16,428,271 | +4.9% | 1,210,877 | 13.57 |
| 2026-05-15 | 15,662,038 | +5.1% | 1,314,747 | 11.91 |
| 2026-04-30 | 14,906,364 | +0.6% | 1,382,538 | 10.78 |
| 2026-04-15 | 14,813,843 | -5.9% | 1,543,208 | 9.60 |
| 2026-03-31 | 15,736,891 | +10.1% | 1,994,558 | 7.89 |
| 2026-03-13 | 14,294,013 | -1.5% | 1,620,294 | 8.82 |
| 2026-02-27 | 14,518,252 | -7.0% | 801,852 | 18.11 |
| 2026-02-13 | 15,619,362 | +0.6% | 934,297 | 16.72 |
| 2026-01-30 | 15,533,415 | -0.8% | 936,586 | 16.59 |
| 2026-01-15 | 15,666,804 | +6.3% | 1,153,820 | 13.58 |
| 2025-12-31 | 14,743,037 | -11.4% | 914,282 | 16.13 |
| 2025-12-15 | 16,646,564 | +4.4% | 1,644,162 | 10.12 |
| 2025-11-28 | 15,949,554 | -7.1% | 2,002,011 | 7.97 |
| 2025-11-14 | 17,166,122 | -4.1% | 2,042,098 | 8.41 |
| 2025-10-31 | 17,901,453 | +5.8% | 2,558,023 | 7.00 |
| 2025-10-15 | 16,920,104 | +3.0% | 3,513,013 | 4.82 |
| 2025-09-30 | 16,419,558 | +2.1% | 3,325,560 | 4.94 |
| 2025-09-15 | 16,075,866 | -4.5% | 1,810,032 | 8.88 |
| 2025-08-29 | 16,829,723 | +8.8% | 1,950,377 | 8.63 |
| 2025-08-15 | 15,466,214 | +4.0% | 1,900,636 | 8.14 |
| 2025-07-31 | 14,868,189 | +4.9% | 1,307,666 | 11.37 |
| 2025-07-15 | 14,173,937 | -0.3% | 999,948 | 14.17 |
| 2025-06-30 | 14,214,531 | -4.8% | 1,860,747 | 7.64 |
| 2025-06-13 | 14,932,097 | +4.9% | 1,059,913 | 14.09 |
| 2025-05-30 | 14,232,577 | -6.4% | 1,027,584 | 13.85 |
| 2025-05-15 | 15,211,664 | -11.5% | 1,074,453 | 14.16 |
| 2025-04-30 | 17,183,434 | +1.3% | 1,296,595 | 13.25 |
| 2025-04-15 | 16,971,737 | +4.3% | 1,771,973 | 9.58 |
| 2025-03-31 | 16,280,493 | +0.9% | 1,322,314 | 12.31 |
| 2025-03-14 | 16,131,337 | +1.1% | 901,564 | 17.89 |
| 2025-02-28 | 15,951,853 | -0.2% | 770,694 | 20.70 |
| 2025-02-14 | 15,982,742 | +2.5% | 721,170 | 22.16 |
| 2025-01-31 | 15,600,497 | -0.3% | 1,033,157 | 15.10 |
| 2025-01-15 | 15,655,815 | +2.0% | 969,413 | 16.15 |
| 2024-12-31 | 15,355,312 | +1.9% | 1,038,641 | 14.78 |
| 2024-12-13 | 15,072,375 | +2.2% | 891,802 | 16.90 |
| 2024-11-29 | 14,746,474 | -2.6% | 1,505,576 | 9.79 |
| 2024-11-15 | 15,144,673 | -1.1% | 945,376 | 16.02 |
| 2024-10-31 | 15,308,880 | +2.5% | 1,144,598 | 13.37 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of SRRK volume is 69.9%, down 21.8 points over the last five sessions. Over the last 30 readings it ranged from 45.3% (5 October 2026) to 91.7% (26 October 2026). The latest reading is in line with the 30-session average of 68.1%, on 278K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 195K | 278K | 69.9% | 2,500 |
| 2026-10-30 | 137K | 281K | 48.7% | 100 |
| 2026-10-29 | 228K | 476K | 48.0% | 103 |
| 2026-10-28 | 271K | 473K | 57.1% | 279 |
| 2026-10-27 | 236K | 279K | 84.6% | 8,128 |
| 2026-10-26 | 294K | 320K | 91.7% | 0 |
| 2026-10-23 | 264K | 458K | 57.6% | 68 |
| 2026-10-22 | 366K | 447K | 81.8% | 0 |
| 2026-10-21 | 1.6M | 1.9M | 87.4% | 30 |
| 2026-10-20 | 481K | 745K | 64.5% | 18 |
| 2026-10-19 | 399K | 481K | 83.0% | 3,070 |
| 2026-10-16 | 1.1M | 1.3M | 85.1% | 9,936 |
| 2026-10-15 | 514K | 973K | 52.8% | 5,000 |
| 2026-10-14 | 273K | 537K | 50.8% | 0 |
| 2026-10-13 | 197K | 333K | 59.1% | 4,882 |
| 2026-10-12 | 192K | 292K | 65.9% | 0 |
| 2026-10-09 | 365K | 453K | 80.6% | 110 |
| 2026-10-08 | 342K | 618K | 55.3% | 0 |
| 2026-10-07 | 360K | 773K | 46.5% | 0 |
| 2026-10-06 | 512K | 794K | 64.5% | 19 |
| 2026-10-05 | 734K | 1.6M | 45.3% | 462 |
| 2026-10-02 | 285K | 470K | 60.7% | 20 |
| 2026-10-01 | 246K | 432K | 57.0% | 378 |
| 2026-09-30 | 323K | 439K | 73.4% | 0 |
| 2026-09-29 | 288K | 410K | 70.3% | 0 |
| 2026-09-28 | 636K | 774K | 82.2% | 37 |
| 2026-09-25 | 513K | 566K | 90.6% | 7 |
| 2026-09-24 | 648K | 928K | 69.8% | 0 |
| 2026-09-23 | 950K | 1.2M | 76.8% | 0 |
| 2026-09-22 | 1.5M | 1.8M | 81.8% | 4 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in SRRK is 177,778 shares, up 97,671 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (10 August 2026) to 177,778 shares (9 October 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 177,778 | $42.20 | $7.5M |
| 2026-09-23 | 80,107 | $51.19 | $4.1M |
| 2026-09-22 | 31,991 | $48.16 | $1.5M |
| 2026-09-17 | 278 | $49.37 | $14K |
| 2026-09-16 | 278 | $50.00 | $14K |
| 2026-09-14 | 13,795 | $55.41 | $764K |
| 2026-09-11 | 220 | $55.67 | $12K |
| 2026-08-28 | 75 | $59.26 | $4K |
| 2026-08-25 | 6,546 | $58.20 | $381K |
| 2026-08-24 | 56 | $56.50 | $3K |
| 2026-08-18 | 1,463 | $52.05 | $76K |
| 2026-08-14 | 15,551 | $53.06 | $825K |
| 2026-08-10 | 1 | $52.92 | $53 |
| 2026-08-06 | 37 | $47.87 | $2K |
| 2026-08-04 | 75,223 | $45.85 | $3.4M |
| 2026-08-03 | 14,693 | $47.30 | $695K |
| 2026-07-27 | 865 | $47.67 | $41K |
| 2026-07-23 | 30 | $48.30 | $1K |
| 2026-06-30 | 5,570 | $54.96 | $306K |
| 2026-06-29 | 6,564 | $54.76 | $359K |
| 2026-06-25 | 3,097 | $52.33 | $162K |
| 2026-06-23 | 10,786 | $49.19 | $531K |
| 2026-06-18 | 56 | $46.95 | $3K |
| 2026-06-17 | 583 | $45.56 | $27K |
| 2026-06-08 | 20,415 | $44.30 | $904K |
| 2026-06-04 | 472 | $44.64 | $21K |
| 2026-05-29 | 99 | $49.82 | $5K |
| 2026-05-27 | 126,922 | $51.51 | $6.5M |
| 2026-05-19 | 96 | $47.38 | $5K |
| 2026-05-15 | 49,068 | $51.28 | $2.5M |
Insider trades
SEC Form 4, newest first. JSONInsiders at SRRK reported 6 open-market buys worth $12.0M in the last 90 days and no open-market sells. Latest filing: AKKARAJU SRINIVAS (Director) on 2026-10-26.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | AKKARAJU SRINIVAS | Director | Buy | 98K | $41.59 | $4.1M | 723K |
| 2026-10-26 | AKKARAJU SRINIVAS | Director | Buy | 49K | $41.59 | $2.0M | 6.4M |
| 2026-10-23 | AKKARAJU SRINIVAS | Director | Buy | 1K | $41.82 | $42K | 625K |
| 2026-10-23 | AKKARAJU SRINIVAS | Director | Buy | 500 | $41.82 | $21K | 6.3M |
| 2026-10-23 | AKKARAJU SRINIVAS | Director | Buy | 94K | $41.31 | $3.9M | 624K |
| 2026-10-23 | AKKARAJU SRINIVAS | Director | Buy | 47K | $41.31 | $1.9M | 6.3M |
| 2026-09-24 | Woods Keith | Chief Operating Officer | Gift | 48K | $0.00 | $0 | 572K |
| 2026-09-21 | Hallal David | Chief Executive Officer | Gift | 37K | $0.00 | $0 | 1.6M |
| 2026-07-01 | Reed Joshua | Director | Sell | 948 | $54.28 | $51K | 20K |
| 2026-07-01 | Reed Joshua | Director | Sell | 2K | $53.50 | $113K | 20K |
| 2026-07-01 | Peng Katie | Director | Sell | 21 | $54.96 | $1K | 34K |
| 2026-07-01 | Peng Katie | Director | Sell | 2K | $54.25 | $132K | 34K |
| 2026-07-01 | Peng Katie | Director | Sell | 3K | $53.56 | $160K | 37K |
| 2026-07-01 | Gilman Michael | Director | Sell | 43 | $54.81 | $2K | 60K |
| 2026-07-01 | Gilman Michael | Director | Sell | 1K | $54.23 | $63K | 60K |
| 2026-07-01 | Gilman Michael | Director | Sell | 1K | $53.54 | $72K | 61K |
| 2026-07-01 | FLIER JEFFREY S. | Director | Sell | 15 | $54.88 | $823 | 28K |
| 2026-07-01 | FLIER JEFFREY S. | Director | Sell | 1K | $54.24 | $80K | 28K |
| 2026-07-01 | FLIER JEFFREY S. | Director | Sell | 2K | $53.53 | $84K | 29K |
| 2026-07-01 | Burow Kristina | Director | Sell | 948 | $54.28 | $51K | 115K |
| 2026-07-01 | Burow Kristina | Director | Sell | 2K | $53.49 | $113K | 116K |
| 2026-06-04 | Reed Joshua | Director | Grant | 7K | $0.00 | $0 | 23K |
| 2026-06-04 | Peng Katie | Director | Grant | 7K | $0.00 | $0 | 40K |
| 2026-06-04 | Gilman Michael | Director | Grant | 7K | $0.00 | $0 | 62K |
| 2026-06-04 | FLIER JEFFREY S. | Director | Grant | 7K | $0.00 | $0 | 31K |
| 2026-06-04 | Burow Kristina | Director | Grant | 7K | $0.00 | $0 | 118K |
| 2026-06-04 | Brudnick Richard | Director | Grant | 7K | $0.00 | $0 | 22K |
| 2026-06-04 | AKKARAJU SRINIVAS | Director | Grant | 7K | $0.00 | $0 | 28K |
| 2026-04-23 | Burow Kristina | Director | Exercise or conversion | 18K | $8.36 | $150K | 111K |
| 2026-04-23 | Burow Kristina | Director | Exercise or conversion | 36K | $9.11 | $328K | 93K |
| 2026-04-23 | Burow Kristina | Director | Exercise or conversion | 28K | $4.75 | $133K | 57K |
| 2026-04-23 | Burow Kristina | Director | Exercise or conversion | 8K | $26.78 | $209K | 29K |
| 2026-04-16 | Woods Keith | Chief Operating Officer | Sell | 10K | $49.57 | $507K | 620K |
| 2026-04-16 | Vaishnaw Akshay | President of R&D | Sell | 12K | $49.57 | $607K | 631K |
| 2026-04-16 | Sinha Vikas | Chief Financial Officer | Sell | 10K | $49.57 | $516K | 620K |
| 2026-04-16 | Hallal David | Chief Executive Officer | Sell | 31K | $49.57 | $1.5M | 1.6M |
| 2026-02-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 200 | $48.48 | $10K | 98K |
| 2026-02-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 857 | $47.86 | $41K | 99K |
| 2026-02-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 7K | $46.94 | $349K | 100K |
| 2026-02-17 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 8K | $46.53 | $372K | 107K |
| 2026-02-17 | Parlavecchio Caryn | CHRO | Sell | 9K | $46.53 | $420K | 169K |
| 2026-02-17 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 4K | $46.53 | $193K | 126K |
| 2026-02-17 | Ho Junlin | GENERAL COUNSEL | Sell | 10K | $46.53 | $446K | 242K |
| 2026-02-09 | Vaishnaw Akshay | President of R&D | Grant | 47K | $0.00 | $0 | 643K |
| 2026-02-09 | Sinha Vikas | Chief Financial Officer | Grant | 47K | $0.00 | $0 | 630K |
| 2026-02-09 | Woods Keith | Chief Operating Officer | Grant | 47K | $0.00 | $0 | 630K |
| 2026-02-09 | Qatanani Mo | Chief Scientific Officer | Grant | 29K | $0.00 | $0 | 115K |
| 2026-02-09 | Parlavecchio Caryn | Chief Human Resources Officer | Grant | 29K | $0.00 | $0 | 178K |
| 2026-02-09 | Marantz Jing L. | Chief Medical Officer | Grant | 34K | $0.00 | $0 | 130K |
| 2026-02-09 | Ho Junlin | General Counsel | Grant | 37K | $0.00 | $0 | 251K |
| 2026-02-09 | Hallal David | Chief Executive Officer | Grant | 128K | $0.00 | $0 | 1.7M |
| 2026-01-22 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 13K | $46.85 | $599K | 86K |
| 2026-01-22 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 2K | $45.87 | $97K | 98K |
| 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 8K | $44.48 | $374K | 101K |
| 2026-01-16 | Parlavecchio Caryn | CHRO | Sell | 7K | $44.48 | $294K | 149K |
| 2026-01-16 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 6K | $44.48 | $258K | 96K |
| 2026-01-16 | Ho Junlin | GENERAL COUNSEL | Sell | 8K | $44.48 | $357K | 215K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 13K | $45.20 | $593K | 109K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 3K | $35.15 | $94K | 122K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 6K | $15.75 | $93K | 119K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 3K | $10.00 | $28K | 114K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 321 | $7.62 | $2K | 111K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 1K | $18.08 | $25K | 110K |
| 2026-01-13 | Sinha Vikas | Chief Financial Officer | Sell | 17K | $42.70 | $715K | 583K |
| 2026-01-13 | Woods Keith | Chief Operating Officer | Sell | 17K | $42.70 | $715K | 583K |
| 2026-01-13 | Vaishnaw Akshay | President of R&D | Sell | 20K | $42.70 | $873K | 596K |
| 2026-01-13 | Hallal David | Chief Executive Officer | Sell | 57K | $42.70 | $2.5M | 1.5M |
| 2025-12-16 | Peng Katie | Director | Sell | 280 | $44.63 | $12K | 33K |
| 2025-12-16 | Peng Katie | Director | Sell | 726 | $43.88 | $32K | 33K |
| 2025-12-12 | AKKARAJU SRINIVAS | Director | Exercise (in or at the money) | 1.1M | $7.35 | $7.8M | 6.4M |
| 2025-12-11 | Siren, L.L.C. | TenPercentOwner | Exercise (in or at the money) | 1.6M | $7.35 | $11.6M | 10.8M |
| 2025-12-11 | Invus Global Management, LLC | 10% owner | Exercise (in or at the money) | 1.6M | $7.35 | $11.6M | 10.8M |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 136K | $45.21 | $6.2M | 109K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 8K | $35.15 | $282K | 245K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 24K | $15.75 | $371K | 237K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 11K | $10.00 | $113K | 214K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 1K | $7.62 | $10K | 203K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 6K | $4.86 | $27K | 201K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 21K | $18.08 | $381K | 196K |
| 2025-12-04 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 66K | $26.05 | $1.7M | 175K |
| 2025-10-08 | Hallal David | Chief Executive Officer | Gift | 205K | $0.00 | $0 | 1.6M |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | Buy | 4K | $40.97 | $180K | 530K |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | Buy | 12K | $40.18 | $498K | 526K |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | Buy | 13K | $39.31 | $503K | 513K |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | Buy | 14K | $39.52 | $543K | 500K |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | Buy | 81K | $38.68 | $3.1M | 487K |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | Buy | 18K | $37.89 | $698K | 406K |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | Buy | 320K | $37.42 | $12.0M | 387K |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | Buy | 57K | $36.74 | $2.1M | 68K |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | Buy | 11K | $35.61 | $392K | 11K |
| 2025-09-22 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3K | $30.67 | $103K | 109K |
| 2025-09-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3K | $33.52 | $107K | 112K |
| 2025-09-16 | Peng Katie | Director | Sell | 76 | $33.20 | $3K | 34K |
| 2025-09-16 | Peng Katie | Director | Sell | 930 | $32.48 | $30K | 34K |
| 2025-08-18 | Parlavecchio Caryn | CHRO | Sell | 2K | $31.17 | $68K | 155K |
| 2025-07-16 | FLIER JEFFREY S. | Director | Sell | 11K | $40.02 | $446K | 0 |
| 2025-07-08 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 24K | $34.44 | $829K | 115K |
| 2025-06-23 | FLIER JEFFREY S. | Director | Sell | 11K | $33.21 | $370K | 11K |
| 2025-06-23 | FLIER JEFFREY S. | Director | Sell | 3K | $32.74 | $91K | 24K |
| 2025-06-23 | FLIER JEFFREY S. | Director | Sell | 18K | $32.16 | $564K | 27K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON7 Form 144 notices on file for SRRK worth $8.9M at the prices reported; 0 in the last 90 days worth $0. Latest: Mohammed Qatanani filed on 2026-04-06 to sell 23,408 shares ($1.2M) from 2026-04-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-04-06 | Mohammed QatananiOfficer | 23K | $1.2M | 0.020% | 2026-04-06 | J.P. Morgan Securities LLC |
| 2026-02-23 | Mohammed QatananiOfficer | 8K | $410K | 0.008% | 2026-02-23 | J.P. Morgan Securities LLC |
| 2026-01-22 | Mohammed QatananiOfficer | 15K | $686K | 0.015% | 2026-01-22 | J.P. Morgan Securities LLC |
| 2025-12-16 | Katie PengDirector | 1K | $46K | 0.001% | 2025-12-16 | J.P. Morgan Securities LLC |
| 2025-12-04 | Mohammed QatananiOfficer | 150K | $6.4M | 0.147% | 2025-12-04 | J.P. Morgan Securities LLC |
| 2025-09-22 | Mohammed QatananiOfficer | 3K | $103K | 0.005% | 2025-09-22 | J.P. Morgan Securities LLC |
| 2025-09-16 | Katie PengDirector | 1K | $33K | 0.001% | 2025-09-16 | J.P. Morgan Securities LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of SRRK in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is Invus Public Equities, L.P. at 8.0% of the class (9,575,013 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 11 | Redmile Group, LLCinvestment adviser, other entity | 4.3M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 11 | Jeremy C. Greenparent holding company, individual | 4.3M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 11 | RedCo II Master Fund, L.P.partnership, non-US institution | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Invus Public Equities, L.P.partnership | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Invus Public Equities Advisors, LLCother entity | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Invus Global Management, LLCother entity | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Siren, L.L.C.other entity | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Raymond Debbaneindividual | 9.6M | 8.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 8 | T. Rowe Price Associates, Inc.investment adviser | 6.2M | 5.4% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-10 | 13G | Wellington Management Group LLPparent holding company | 5.8M | 5.6% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Group Holdings LLPparent holding company | 5.8M | 5.6% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Investment Advisors Holdings LLPparent holding company | 5.8M | 5.6% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Management Company LLPinvestment adviser | 5.8M | 5.3% | 2025-12-31 |
| 2025-10-07 | 13D/Ano. 3 | Srinivas Akkarajuindividual | 7.0M | 7.2% | 2025-10-03 |
| 2025-10-07 | 13D/Ano. 3 | Samsara BioCapital, L.P.partnership | 6.4M | 6.6% | 2025-10-03 |
| 2025-10-07 | 13D/Ano. 3 | Samsara BioCapital GP, LLCother entity | 6.4M | 6.6% | 2025-10-03 |
| 2025-10-07 | 13D/Ano. 3 | Samsara Opportunity Fund, L.P.partnership | 500K | 0.5% | 2025-10-03 |
| 2025-10-07 | 13D/Ano. 3 | Samsara Opportunity Fund GP, LLCother entity | 500K | 0.5% | 2025-10-03 |
13F holders
Tracked managers holding SRRK at their latest 13F. JSON7 of the 30 tracked managers held SRRK at their latest 13F, $76.1M in total at quarter-end prices. Fisher Asset Management is the largest at $24.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Fisher Asset Management | 2026-06-30 | 439K | $24.2M | 0.01% | -19K |
| Citadel Advisors | 2026-06-30 | 332K | $18.3M | 0.00% | -569K |
| AQR Capital Management | 2026-06-30 | 248K | $13.6M | 0.00% | +36K |
| D. E. Shaw & Co. | 2026-06-30 | 245K | $13.5M | 0.01% | +230K |
| Renaissance Technologies | 2026-06-30 | 92K | $5.0M | 0.01% | new |
| Millennium Management | 2026-06-30 | 18K | $994K | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 10K | $525K | 0.00% | -169K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$300.0M of operating cash flow. As of 2026-06-30, cash was $437.1M against $196.2M of debt.
- Cash
- $437.1M
- Debt
- $196.2M
- Equity
- $253.8M
- Total assets
- $523.5M
- Shares outstanding
- 121,785,282
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$109.9M | n/a | -0.84 |
| Q1 FY 2026 | 2026-03-31 | $0 | -$105.5M | n/a | -0.83 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$91.0M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$102.2M | n/a | -0.90 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$110.0M | n/a | -0.98 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$74.7M | n/a | -0.67 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$66.5M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$64.5M | n/a | -0.66 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | -$377.9M | -$300.0M | $602K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$246.3M | -$200.9M | $98K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$165.8M | -$145.2M | $71K | n/a | n/a |
| FY 2022 | 2022-12-31 | $33.2M | -$134.5M | -$132.7M | $1.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $18.8M | -$131.8M | -$126.8M | $5.2M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Scholar Rock Holding in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Scholar Rock Holding (SRRK), SEC CIK 1727196, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-04-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-26.JSON and CSV
- Company record
- EDGAR filing index for CIK 1727196Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of SRRK is sold short?
22,175,999 shares were held short at the 2026-10-15 settlement, 12.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SRRK's daily short volume?
On 2026-11-02, 194,616 of the 278,307 SRRK shares reported to FINRA were sold short, 69.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SRRK have fails to deliver?
The SEC's latest file shows 177,778 SRRK shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are SRRK insiders buying or selling?
Insiders at SRRK reported 6 open-market buys worth $12.0M in the last 90 days and no open-market sells. Latest filing: AKKARAJU SRINIVAS (Director) on 2026-10-26.
Have SRRK insiders filed to sell?
7 Form 144 notices on file for SRRK worth $8.9M at the prices reported; 0 in the last 90 days worth $0. Latest: Mohammed Qatanani filed on 2026-04-06 to sell 23,408 shares ($1.2M) from 2026-04-06.
Who owns 5% or more of SRRK?
13 holders report 5% or more of SRRK in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is Invus Public Equities, L.P. at 8.0% of the class (9,575,013 shares), filed 2026-08-13 for an event on 2026-06-30.
What did SRRK report last quarter?
In FY 2025 it generated -$300.0M of operating cash flow. As of 2026-06-30, cash was $437.1M against $196.2M of debt.
Which tracked 13F managers own SRRK?
7 of the 30 tracked 13F managers held SRRK shares at their latest filing, $76.1M in all. The largest: Ken Fisher's Fisher Asset Management (439K shares, $24.2M), Ken Griffin's Citadel Advisors (332K shares, $18.3M), Cliff Asness's AQR Capital Management (248K shares, $13.6M), D. E. Shaw & Co. (245K shares, $13.5M), Renaissance Technologies (92K shares, $5.0M), Izzy Englander's Millennium Management (18K shares, $994K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.